Introduction: Congenital heart disease (CHD) is the most frequent birth defect. As survival has significantly improved, attention has turned to neurodevelopmental outcomes of children undergoing heart surgery in early infancy. Since multiple risk factors contribute to neurodevelopmental alterations, a nationwide registry collecting data on medical characteristics, interventions, clinical course and neurodevelopment until school-age is needed to improve the quality of management, identify risk- and protective factors affecting neurodevelopment, and facilitate multicenter trials.
Methods and analysis: The Swiss Outcome Registry for CHIldren with severe congenital heart Disease (ORCHID) is a nationwide, prospective, population-based patient registry developed (1) to collect baseline characteristics and clinical data of CHD patients operated with bypass-surgery or hybrid procedures in the first 6 weeks of life in Switzerland, (2) to monitor long-term neurodevelopment, and (3) to relate clinical characteristics and neurodevelopment to identify risk and protective factors in these children. This registry started data collection relating to pregnancy, birth, preoperative course, catheter-based and surgical treatment, postoperative course and reinterventions in 2019. The primary outcome includes standardised neurodevelopmental assessments at 9 to 12 months, 18 to 24 months and 5.5 to 6 years. Investigators expect to include 80 to 100 children per year. Correlation and regression analyses will be used to investigate risk- and protective factors influencing neurodevelopment.
Ethics and dissemination of results: Swiss ORCHID received support by the Accentus Charitable Foundation, the Anna Mueller Grocholoski Foundation, the Swiss Society of Pediatric Cardiology, and the Corelina - Foundation and was approved by the cantonal ethics committees. Findings will be presented at national and international scientific meetings, and published in peer-reviewed journals. Results will also be shared with patient organizations, primary health care providers, and public health stakeholders to ensure a widespread dissemination of the results.
Neonates (including preterm born children) with severe CHD
Requiring an invasive cardiac intervention (including heart-lung-machine) within the first 6 weeks of life.
Neonates (including preterm born children) with simple CHD
Requiring simple cardiac surgery or catheter intervention such as closure of patent arterial duct or simple repair of aortic coarctation without heart-lung-machine and low impact on neurodevelopmental outcome.
Patients with severe CHD
Cohort
Prospective
Not listed
Bayley scales of infant and toddler development III at one year of age
Neurodevelopmental outcome measurement at one year of age (normal value 100, higher values mean better outcome)
Bayley scales of infant and toddler development III at two years of age
Neurodevelopmental outcome measurement at two years of age (normal value 100, higher values mean better outcome)
Bayley scales of infant and toddler development III at five years of age
Neurodevelopmental outcome measurement at five years of age (normal value 100, higher values mean better outcome)
Click on the lead sponsor to view all of their trials.
University Children's Hospital, Zurich
Lead sponsor
University of Lausanne Hospitals
Collaborator
University of Geneva, Switzerland
Collaborator
University of Bern
Collaborator
